India’s pharmaceutical companies are likely to see FY24 year-on-year growth in US market revenues slow down to 6-8% from 16% seen in FY23, based on its coverage universe of 25 companies, rating agency ICRA recently estimated.
US Regulatory Risks, Litigation Likely To Slow FY24 Growth For India’s Top Pharma Firms, Says ICRA
Pfizer Plant Damage Presents Opportunity
The damage at one of Pfizer’s largest injectables facilities could lead to gains for a few Indian companies, analysts feel. However, regulatory risks, litigation pay-outs and other challenges will slow growth for domestic firms and Indian units of multinationals like Abbott and Pfizer in FY24, says rating agency ICRA as Q1 results begin coming in
More from Business
After a less auspicious prelude and a positive start to the biggest healthcare conference of the year, the news flow and investors’ support for biotech initially improved.
A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.
What do industry leaders anticipate as the US installs president Trump once again? Beyond the biopharma sector's biggest market, geopolitical instability has increased elsewhere: how might this affect markets and companies?
In this week's episode: a look at JPM; J&J’s Intra-Cellular buy; how JPM Day 1 deals fit into BD strategy; Scrip asks about the global state of biopharma; and what will fuel M&A activity in India this year.